Article
04 June 2021 - by Elizabeth Anne Jackson, Brenda Runyan, Luke Metz, James Kenney
複数年の支払方式の評価:希少疾患患者の継続率の評価
Article
04 June 2021 - by Elizabeth Anne Jackson, Brenda Runyan, Luke Metz, James Kenney
Evaluating multiyear payment arrangements? Assess retention rates for patients with rare diseases.
Article
07 January 2020 - by Robert Bachler, Elizabeth Anne Jackson, Jessica Naber, Brenda Runyan
This paper introduces why self-insured employers with stop-loss coverage may still be exposed to some of the costs of gene and cell therapies, explores considerations and a potential imbalance of financial risk for the self-insured employer and stop-loss carrier when implementing a multiyear performance-based payment arrangement, and discusses potential ways to efficiently contract between the self-insured employer, stop-loss carrier, and manufacturer to better share the financial risk.
Article
07 January 2020 - by Elizabeth Anne Jackson, Jessica Naber, Brenda Runyan
What is the potential financial exposure related to gene and cell therapies for a self-insured employer without stop-loss coverage and how could a partnering manufacturer and/or third-party administrator aid in smoothing a self-insured employer’s costs for gene and cell therapies?
Article
06 February 2019 - by Jessica Naber, Elizabeth Anne Jackson
遺伝子治療や細胞治療となると、支払者が考慮すべき多くのリスクと利点があります。
Article
06 February 2019 - by Jessica Naber, Elizabeth Anne Jackson
When it comes to gene and cell therapies, there are a number of risks and benefits that payers should consider.
Article
03 October 2018 - by Elizabeth Anne Jackson, Melanie K. Kuester, Brenda Runyan
Insurers, policymakers, and government agencies in the United States may find it useful to have an accurate expectation for the length of enrollment by subscribers with a dependent who suffers from a pediatric rare disease and may be a candidate for a regenerative therapy with a potentially prolonged benefit.
Article
30 May 2018 - by Joanne Buckle, Elizabeth Anne Jackson, Jessica Naber
Payers and manufacturers of curative therapies are beginning to contemplate ways to mitigate, share, or distribute the risks and costs associated with these therapies.
Article
27 March 2017 - by Matt Berman, Elizabeth Anne Jackson
This analysis identifies tactics plan administrators could adopt that would reduce out-of-pocket costs for brand-name drugs.
Article
26 January 2017 - by Elizabeth Anne Jackson, Jessica Naber
Treating patients with gene therapies could avoid years of medical and drug expenses for both patients and payers.